Developer docs
API playgroundTry for free, no card

Search company profiles

Lyka Labs

Full company profile

uuid0006bn4

Namestring
Lyka Labs
Legal namestring
Lyka Labs Limited
Websiteurl
lykalabs.com
Company typeenum
Public
Founded yearint
1976
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulations, active pharmaceutical ingredients, contract manufacturing, lyophilized injections, topical formulations
Industry3 codes
1GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
CodeHLAGAHALPrimaryYes
2Analytical Development & QC Testing (Release/Stability/Potency)
CodeHLAGAGAFPrimaryNo
3Release Testing & Batch Certification (QC)
CodeHLAGADACPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from manufacturing and selling pharmaceutical formulations including lyophilized injections, topical formulations (creams, ointments, foams, gels, lotions), and Active Pharmaceutical Ingredients (APIs) to healthcare providers and pharmaceutical companies.

lykalabs.com
2Contract Manufacturing (P2P)
TypeOne Time License
Description

Put-to-Publish (P2P) manufacturing services for pharmaceutical companies requiring contract manufacturing capabilities.

lykalabs.com
3In-Licensing Opportunities
TypeLicensing Royalties
Description

In-licensing arrangements for products from other pharmaceutical companies.

lykalabs.com
4Out-Licensing
TypeLicensing Royalties
Description

Out-licensing of proprietary products to other pharmaceutical companies, including international licensing deals with US-based generics companies.

lykalabs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lyka Labs Limited manufactures pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) at a WHO-GMP and ISO 9001:2000 certified facility in Ankleshwar, Gujarat, producing lyophilized injections and topical formulations (creams, ointments, foams, gels, and lotions) across multiple therapeutic segments. The company also offers P2P contract manufacturing services, in-licensing and out-licensing arrangements, and R&D-driven formulation development through a Mumbai-based research facility.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lyka Labs operates as a pharmaceutical manufacturing company offering a portfolio of products and services centered on Pharmaceutical Formulations and Active Pharmaceutical Ingredients (APIs). The core product portfolio includes Lyophilized injections and topical formulations (creams, ointments, foams, gels, lotions) manufactured at WHO-GMP certified facilities. Supporting services include P to P Manufacturing, In-Licencing Opportunity, and Out-Licencing arrangements. The company also maintains R&D capabilities through its Mumbai facility providing Innovation & Technology, Formulation Development, Core Competencies, and Platform Technology services. All manufacturing is conducted at ISO 9001-certified facilities in Ankleshwar, Gujarat.

Product and service5 records
1Pharmaceutical Formulations
CategoryPharmaceutical Formulations Manufacturing
Description

Wide range of pharmaceutical formulations including lyophilized injections and topical formulations (creams, ointments, foams, gels, and lotions) manufactured at WHO-GMP certified facilities across various therapeutic segments for pharmaceutical companies and healthcare providers.

2Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredient Manufacturing
Description

Active Pharmaceutical Ingredients (APIs) manufactured by Lyka Labs as part of its core pharmaceutical manufacturing business, serving pharmaceutical companies and healthcare providers.

3P to P Manufacturing (Put-to-Publish Contract Manufacturing)
CategoryContract Manufacturing Services
Description

Point-to-Point (P2P) manufacturing service offering for pharmaceutical products, providing contract manufacturing capabilities to pharmaceutical companies seeking production partners.

4In-Licensing Opportunity
CategoryPharmaceutical Licensing Services
Description

In-licensing opportunity service that brings external pharmaceutical products into Lyka Labs' manufacturing and distribution network for partner pharmaceutical companies.

5Out-Licensing
CategoryPharmaceutical Licensing Services
Description

Out-licensing service through which Lyka Labs grants rights to external parties, including international partners and US-based generics companies, for its proprietary pharmaceutical products.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Lyka Healthcare Ltd
Strategic tierMajorTypeOthers
Description

Merger of Lyka Healthcare Ltd with Lyka Labs Ltd, consolidating operations and expanding the company's pharmaceutical manufacturing capabilities and market presence.

lykalabs.com
2Lyka Exports Limited
Strategic tierMajorTypeOthers
Description

Merger of Lyka Exports Limited with Lyka Labs Limited, integrating export operations into the main company structure.

lykalabs.com
3US-Based Generics Company
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Out-licensing deal with a US-based generics company for proprietary pharmaceutical products, representing international market expansion through product licensing.

lykalabs.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers5 records
1Aurobindo Pharma
TypeBroad incumbent
Description

Vertically integrated Indian pharmaceutical company with strong API and formulations manufacturing, including injectables. Comparable to Lyka in the formulations and API manufacturing domain but operates at significantly larger scale globally.

2Torrent Pharmaceuticals
TypeRegional player
Description

Indian pharmaceutical manufacturer focused on branded generics and APIs across therapeutic areas. Direct competitor in the Indian formulations market with comparable regulatory positioning.

3Ipca Laboratories
TypeDirect peer
Description

Indian pharmaceutical manufacturer focused on APIs and formulations across therapeutic segments. Ipca's 2021 open offer for Lyka demonstrates direct strategic overlap and competitive positioning in the same Indian mid-market formulations space.

4Cipla
TypeBroad incumbent
Description

One of India's largest generic pharmaceutical manufacturers with extensive API and finished dosage form capabilities. While far larger and more diversified than Lyka, Cipla competes directly in formulations manufacturing and contract manufacturing services.

5Glenmark Pharmaceuticals
TypeBroad incumbent
Description

India-based pharmaceutical company with significant formulations and API manufacturing capabilities. Comparable to Lyka in its India-based manufacturing footprint and generic formulations focus, but at much greater scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyka Labs

Pharmaceutical Manufacturinglykalabs.com

Lyka Labs firmographics

Firmographics
Name
Lyka Labs
Legal name
Lyka Labs Limited
Website
https://lykalabs.com
Company type
Public
Founded year
1976
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Lyka Labs industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry
GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
akta.pro secondary industries
Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Release Testing & Batch Certification (QC) (HLAGADAC)

Keywords

  • Pharmaceutical formulations
  • Active pharmaceutical ingredients
  • Contract manufacturing
  • Lyophilized injections
  • Topical formulations

Where Lyka Labs is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices3 records

Markets served

Lyka Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical formulations including lyophilized injections, topical formulations (creams, ointments, foams, gels, lotions), and Active Pharmaceutical Ingredients (APIs) to healthcare providers and pharmaceutical companies.
  2. Contract Manufacturing (P2P): Put-to-Publish (P2P) manufacturing services for pharmaceutical companies requiring contract manufacturing capabilities.
  3. In-Licensing Opportunities: In-licensing arrangements for products from other pharmaceutical companies.
  4. Out-Licensing: Out-licensing of proprietary products to other pharmaceutical companies, including international licensing deals with US-based generics companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Lyka Labs product offering

Product offering

Core offering

Lyka Labs Limited manufactures pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) at a WHO-GMP and ISO 9001:2000 certified facility in Ankleshwar, Gujarat, producing lyophilized injections and topical formulations (creams, ointments, foams, gels, and lotions) across multiple therapeutic segments. The company also offers P2P contract manufacturing services, in-licensing and out-licensing arrangements, and R&D-driven formulation development through a Mumbai-based research facility.

Product overview

Lyka Labs operates as a pharmaceutical manufacturing company offering a portfolio of products and services centered on Pharmaceutical Formulations and Active Pharmaceutical Ingredients (APIs). The core product portfolio includes Lyophilized injections and topical formulations (creams, ointments, foams, gels, lotions) manufactured at WHO-GMP certified facilities. Supporting services include P to P Manufacturing, In-Licencing Opportunity, and Out-Licencing arrangements. The company also maintains R&D capabilities through its Mumbai facility providing Innovation & Technology, Formulation Development, Core Competencies, and Platform Technology services. All manufacturing is conducted at ISO 9001-certified facilities in Ankleshwar, Gujarat.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Formulations Wide range of pharmaceutical formulations including lyophilized injections and topical formulations (creams, ointments, foams, gels, and lotions) manufactured at WHO-GMP certified facilities across various therapeutic segments for pharmaceutical companies and healthcare providers.
  • Active Pharmaceutical Ingredients (APIs) Active Pharmaceutical Ingredients (APIs) manufactured by Lyka Labs as part of its core pharmaceutical manufacturing business, serving pharmaceutical companies and healthcare providers.
  • P to P Manufacturing (Put-to-Publish Contract Manufacturing) Point-to-Point (P2P) manufacturing service offering for pharmaceutical products, providing contract manufacturing capabilities to pharmaceutical companies seeking production partners.
  • In-Licensing Opportunity In-licensing opportunity service that brings external pharmaceutical products into Lyka Labs' manufacturing and distribution network for partner pharmaceutical companies.
  • Out-Licensing Out-licensing service through which Lyka Labs grants rights to external parties, including international partners and US-based generics companies, for its proprietary pharmaceutical products.

Companies that use Lyka Labs

Customer profile

Segments2 records

Ideal customer profiles2 records

Lyka Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lyka Labs partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • Lyka Healthcare LtdmajorOthersMerger of Lyka Healthcare Ltd with Lyka Labs Ltd, consolidating operations and expanding the company's pharmaceutical manufacturing capabilities and market presence.
  • Lyka Exports LimitedmajorOthersMerger of Lyka Exports Limited with Lyka Labs Limited, integrating export operations into the main company structure.
  • US-Based Generics CompanycoreStrategic or Co-development PartnerOut-licensing deal with a US-based generics company for proprietary pharmaceutical products, representing international market expansion through product licensing.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Lyka Labs competitors and assessment

Company assessment

Broad incumbents

  • Aurobindo Pharma: Vertically integrated Indian pharmaceutical company with strong API and formulations manufacturing, including injectables. Comparable to Lyka in the formulations and API manufacturing domain but operates at significantly larger scale globally.
  • Cipla: One of India's largest generic pharmaceutical manufacturers with extensive API and finished dosage form capabilities. While far larger and more diversified than Lyka, Cipla competes directly in formulations manufacturing and contract manufacturing services.
  • Glenmark Pharmaceuticals: India-based pharmaceutical company with significant formulations and API manufacturing capabilities. Comparable to Lyka in its India-based manufacturing footprint and generic formulations focus, but at much greater scale.

Regional players

  • Torrent Pharmaceuticals: Indian pharmaceutical manufacturer focused on branded generics and APIs across therapeutic areas. Direct competitor in the Indian formulations market with comparable regulatory positioning.

Direct peers

  • Ipca Laboratories: Indian pharmaceutical manufacturer focused on APIs and formulations across therapeutic segments. Ipca's 2021 open offer for Lyka demonstrates direct strategic overlap and competitive positioning in the same Indian mid-market formulations space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Lyka Labs social profiles

Digital presence

Lyka Labs compliance and trust

Trust signal

Compliance2 records

Lyka Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyka Labs leadership team

Management profile

Number of profiles

Profiles2 records

Lyka Labs subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Lyka Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyka Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyka Labs

What does Lyka Labs do?

Lyka Labs Limited manufactures pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) at a WHO-GMP and ISO 9001:2000 certified facility in Ankleshwar, Gujarat, producing lyophilized injections and topical formulations (creams, ointments, foams, gels, and lotions) across multiple therapeutic segments. The company also offers P2P contract manufacturing services, in-licensing and out-licensing arrangements, and R&D-driven formulation development through a Mumbai-based research facility.

Is Lyka Labs a public or private company?

Lyka Labs is a public company. It is classified as public and is currently operating.

When was Lyka Labs founded?

Lyka Labs was founded in 1976. It employs 251 to 500 people.

Where is Lyka Labs based?

Lyka Labs is headquartered in Mumbai, India, in the Asia region.

How does Lyka Labs make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing (P2P), in-Licensing Opportunities and out-Licensing.

Who are Lyka Labs's main competitors?

Broad incumbents on record are Aurobindo Pharma, Cipla and Glenmark Pharmaceuticals. Torrent Pharmaceuticals is listed as a regional player. Ipca Laboratories is listed as a direct peer.

Does Lyka Labs have an API?

No public API is recorded for Lyka Labs.

What industry is Lyka Labs in?

Lyka Labs's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business News TodayLyka Labs Consolidated June 2026 Net Sales at Rs 42.31 crore, up 28.11% Y-o-Y- Moneycontrol.comLyka Labs reported consolidated net sales of Rs 42.31 crore for June 2026, representing a 28.11% year-over-year increase from the previous period. The company also saw its quarterly net profit rise by 121.45% to Rs 2.07 crore, while EBITDA grew by 15.05% to Rs 4.97 crore.Business StandardLyka Labs consolidated net profit rises 122.58% in the June 2026 quarterLyka Labs reported a 122.58% year-over-year increase in consolidated net profit to Rs 2.07 crore for the quarter ended June 2026, up from Rs 0.93 crore in the same quarter of 2025. The company's sales also grew 28.10% to Rs 42.31 crore from Rs 33.03 crore during the same period. Operating profit margin stood at 10.75% during the quarter.ScanXLyka Labs promoters acquire shares worth ₹39.46 lakhPromoters of Lyka Labs Limited acquired 55,967 equity shares through open market purchases on June 24 and June 25, 2026, totaling ₹39.46 lakh, with the transactions disclosed to BSE and NSE on June 26, 2026. The acquisitions were made by Kunal Gandhi, Nehal Gandhi, Alisha Gandhi, and Enai Trading and Investment Private Limited on the NSE, increasing their collective stake in the company.Business StandardLyka Labs reports consolidated net loss of Rs 7.61 crore in the March 2026 quarterLyka Labs reported a consolidated net loss of Rs 7.61 crore for the quarter ended March 2026, reversing from a net profit of Rs 1.77 crore in the same quarter of the previous year, with sales declining 16.15% to Rs 28.03 crore. For the full year ended March 2026, the company posted a net loss of Rs 10.03 crore compared to a net profit of Rs 8.01 crore the prior year, while annual sales fell 7.26% to Rs 128.44 crore. The financial deterioration reflects a sharp decline in both quarterly and annual performance metrics.Business StandardLyka Labs reports consolidated nil net profit/loss in the December 2025 quarterLyka Labs reported no net profit/loss in the December 2025 quarter, a decline from a net profit of Rs 2.70 crore in the same period the previous year. The company's sales decreased by 9.08% to Rs 30.73 crore compared to the previous year's quarter. The report indicates a downturn in financial performance for the company during this period.MintIpca Labs approves acquisition of 26.5% stake in Lyka Labs | Company Business NewsIpca Labs has approved the acquisition of a 26.574% stake in Lyka Labs for Rs. 97.89 crore, alongside entering into a joint management control agreement with Lyka's promoters. This strategic move enables Ipca to enter the lucrative lyophilized injectables business while leveraging Lyka's manufacturing capabilities in India and global markets.